ADMET Prediction of Dual PPARα/γ Agonists for Identification of Potential Anti-diabetic Agents
Since last 15 years, ex vivo experimental tools to describe ADME–Tox profiles of molecules have been exercised in initial stages of the drug development process to enhance the success percentage of discovery index and to ameliorate better candidates into drug discovery. Implementation of in silico ADMET prediction has further improved discovery support, allowing virtual screening of chemical compounds and therefore, application of ADMET property prediction at each phase of the drug development process. Recently there have been advancements in the approaches used to determine the accurateness of the prediction as well as application domain of the absorption, metabolism, distribution, excretion, and toxicity models. Developments also seen in the methods used to anticipate the physiochemical properties of leads in the initial steps of drug development. Absorption, distribution, metabolism, and excretion, ADME parameters, were calculated to investigate pharmacokinetic properties of hit compounds for the screening of new and potent anti-diabetic agents. ADME studies on a set of ligand molecules were performed by DruLiTo software. This study would permit chemists and drug-metabolism researchers to focus on compounds having maximum likelihoods of meeting the essential ADME criteria, also would add to a fall in compound attrition at late-stage.
KeywordsADMET Pharmacokinetic properties Anti-diabetic agents
Author Neha Verma would like to acknowledge the UGC, Delhi for providing RGNFSC fellowship.
- 3.Vaseem, A., Sethi, B., Kelwade, J., Ali, M.: SGLT2 inhibitor and DPP4 inhibitor co-administration in Type 2 diabetes—Are we near the “Promised Land”? Res. Rev. J. Pharmacol. Toxicol. Stud. 4, 6–11 (2016)Google Scholar
- 5.International Diabetes Federation 2012, 5th edn. The Global BurdenGoogle Scholar
- 8.UK Prospective Diabetes Study Group: Overview of 6 years’ therapy of Type II diabetes: a progressive disease. Diabetes 44, 1249–1258 (1995)Google Scholar
- 10.Naidenow, J., Hrgovic, I., Doll, M., Jahn, T.H., Lang, V., Kleemann, J., Kippenberger, S., Kaufmann, R., Zoller, N., Meissner, M.: Peroxisome proliferator-activated receptor (PPAR) α and δ activators induce ICAM-1 expression in quiescent non stimulated endothelial cells. J. Inflamm. 13, 27 (2016)CrossRefGoogle Scholar
- 12.Hansen, M.K., Connolly, T.M.: Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr. Opin. Investig. Drugs 9, 247–255 (2008)Google Scholar
- 17.Monsalve, F.A., Pyarasani, R.D., Delgado-Lopez, F., Moore-Carrasco, R.: Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediat. Inflamm. 549627 (2013)Google Scholar
- 19.Lohray, B.B., Lohray, V.B., Bajji, A.C., Kalchar, S., Poondra, R.R., Padakanti, S., Chakrabarti, R., Vikramadithyan, R.K., Misra, P., Juluri, S., Mamidi, N.V.S.R., Rajagopalan, R.: (−)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(−)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. 44, 2675–2678 (2001)CrossRefGoogle Scholar
- 24.DruLiTO: Drug likeness tool. http://www.niper.gov.in/pi_dev_tools/DruLiToWeb/DruLiTo_index.html